The company plans to extend its CRISPR-based diagnostics platform to point-of-care detection of pathogens and antimicrobial resistance genes associated with hospital-acquired infections
CrisprBits has raised 250,000 USD in pre-seed funding from US-based VJ Group. The funding will be used towards product development, team expansion and for research and development.
Founded by Dr Vijay Chandru, Sunil Arora, Dr Rajeev Kohli, Bharat Jobanputra, and Aditya Sarda in 2020, CrisprBits was started with an aim of developing healthcare solutions in diagnostics and gene editing.
The company plans to extend its CRISPR-based diagnostics platform to point-of-care detection of pathogens and antimicrobial resistance genes associated with hospital-acquired infections. CRISPR is used by bacteria to protect themselves from invading viruses and in the past few years, scientists have harnessed the power of CRISPR to develop therapeutics as well as other biotechnological products in the domains of human, plant & microbial bio-engineering.
Very recently, the company developed OmiCrisp, a CRISPR- based test to detect SARS-CoV2 and to determine whether it is an Omicron or non-omicron variant. The test was developed with support and collaboration from the C-CAMP-InDx (Indigenisation of Diagnostics Program), an initiative supported by the Department of Biotechnology.
- Advertisement -